A novel coronavirus t cell antigen epitope peptide and application thereof in preparation of vaccine

By preparing a pMHC complex of novel coronavirus T-cell antigenic epitope peptides, the problem of insufficient T-cell activation in existing technologies has been solved, achieving effective immune protection and detection of novel coronavirus mutant strains, and is applicable to the development of novel coronavirus vaccines and drugs.

CN116396366BActive Publication Date: 2026-07-03JINAN UNIVERSITY +1
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
JINAN UNIVERSITY
Filing Date
2022-02-24
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

Current technologies have not yet developed universal vaccines and broad-spectrum therapeutics that can effectively activate T cells and prevent immune escape from novel coronavirus mutant strains, especially key molecules that can still provide immune protection after viral antigen mutations.

Method used

The novel coronavirus T-cell antigenic epitope peptide was prepared and expressed using recombinant genetic engineering technology to form a pMHC complex or antigen peptide-antigen presenting cell complex, thereby activating T cells, detecting and inducing immune responses. This method is applicable to the development of novel coronavirus vaccines and drugs.

Benefits of technology

These novel coronavirus T-cell antigenic epitope peptides can effectively activate T cells, detect antigen-specific T cells, and be used for the research, development, detection, and broad-spectrum treatment of novel coronavirus vaccines, prevent immune escape by mutant strains, evaluate vaccine efficacy, and monitor disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116396366B_ABST
    Figure CN116396366B_ABST
Patent Text Reader

Abstract

This invention discloses a novel coronavirus T-cell antigenic epitope peptide and its application in vaccine preparation. The amino acid sequence of the novel coronavirus T-cell antigenic epitope peptide is shown in any one of SEQ ID NO: 1 to 9. A pMHC complex monomer was prepared using this peptide, and a pMHC complex polymer was further prepared. These can be used to detect antigen-specific T cells in the peripheral blood of novel coronavirus vaccine recipients and recovered patients, and for in vitro T-cell activation experiments. These novel coronavirus T-cell antigenic epitope peptides can be used in the preparation of universal vaccines against various novel coronavirus mutant strains, novel coronavirus-related immune detection, and the development of broad-spectrum therapeutic drugs, and are worthy of in-depth research and widespread promotion.
Need to check novelty before this filing date? Find Prior Art